Advancing Cell Therapy
With more than 20 years of experience in tissue engineering, TETEC develops personalized cell therapies for the treatment of knee cartilage defects, with the aim of preserving joint function and supporting patients’ long-term mobility, independence, and quality of life. Learn more by selecting the information most relevant to you.
The Future of Cartilage Regeneration for the Knee
As part of the Octane Medical Group, we are continuously advancing established procedures for biological cartilage repair while developing innovative technologies that could make autologous cell transplants more efficient and bring these advanced therapies closer to the point of care in the future. Our goal is to further improve treatment options for patients with cartilage defects and support the future use of regenerative cell therapies in additional medical indications.
Cell-Based Cartilage Regeneration for the Knee
TETEC offers two matrix-associated autologous chondrocyte transplantation (MACT) procedures for the treatment of knee cartilage defects: Injectable MACT and Scaffold-Based MACT.
Injectable MACT
Injectable MACT is a cell-based procedure for the treatment of focal cartilage defects of the knee. The procedure uses a patient's own cartilage cells in combination with an injectable hydrogel for transplantation into the cartilage defect [1]. In clinical studies and earlier publications, this procedure has also been referred to as hydrogel-based ACI or Injectable M-ACI.
- A patient's own cartilage cells suspended in an injectable hydrogel
- Minimally invasive arthroscopic transplantation
- May be performed on an inpatient or outpatient basis, depending on the indication
Scaffold-Based MACT
In Scaffold-Based MACT, a patient's own cartilage cells are seeded onto a collagen-based scaffold and transplanted into the cartilage defect [2].
- Collagen-based scaffold seeded with a patient's own cartilage cells
- Transplantation via a small surgical approach (mini-arthrotomy)
- May be performed on an inpatient or outpatient basis, depending on the indication
Proven in Clinical Practice
Autologous cell transplants manufactured by TETEC have been used in more than 30,000 autologous chondrocyte transplantation procedures in Germany for the treatment of focal cartilage defects of the knee [3].
Our Network of Excellence
TETEC partners with leading academic, clinical, and industrial organizations to advance research and therapeutic development in regenerative medicine.
Discover Our Facility
Learn how our controlled manufacturing conditions and expert oversight help ensure product quality.
Stay Up to Date with TETEC
Keep up with the latest developments at TETEC, upcoming congresses, and scientific meetings.
Grow Your Career at TETEC
Join our team and help shape the future of regenerative medicine. We offer a wide range of opportunities in manufacturing, quality assurance, and research, all focused on advancing personalized cell therapies for the treatment of cartilage defects of the knee.
.avif)
1. TETEC AG. Summary of Product Characteristics (SmPC) NOVOCART® Inject. Reutlingen (DE): TETEC AG; 2026. Revision date: 02/2026. PEI.A.11763.01.1.
2. TETEC AG. Summary of Product Characteristics (SmPC) NOVOCART® 3D. Reutlingen (DE): TETEC AG; 2023. Revision date: 11/2023. PEI.A.11511.01.1.
3. TETEC AG. Internal registry and documentation of Injectable MACT and Scaffold-Based MACT procedures performed in Germany. Reutlingen (DE): TETEC AG; 2025.